Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Reduce” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been given a consensus rating of “Reduce” by the ten ratings firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $4.8750.

Several research analysts have commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $8.00 price target for the company in a research note on Friday, May 29th. HC Wainwright reiterated a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Finally, Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently bought and sold shares of REPL. International Assets Investment Management LLC purchased a new stake in Replimune Group in the fourth quarter worth $29,000. CWM LLC boosted its stake in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after purchasing an additional 2,886 shares during the period. Essential Partners LLC boosted its stake in shares of Replimune Group by 562,400.0% during the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter worth about $69,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

NASDAQ:REPL opened at $9.24 on Wednesday. The stock’s fifty day moving average is $5.18 and its 200 day moving average is $7.27. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $13.24. The firm has a market capitalization of $762.95 million, a PE ratio of -2.69 and a beta of 0.91. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.